Regenics are in the process of exploring funding for  several indications   in addition to Vernex® for wound healing. The indication for treating mild to moderate atopic dermatitis with a topical formulation is in funding process. The market is very large, with a high unmet medical need in particular for topical treatment of infants and children.

Due to the safety profile of Regenics bioactives, a pediatric indication is assumed to be viable

The indication has not been explored clinically at this stage. 

 

 

 

Scientifically documented and patented claims in atopic dermatitis (tbc):

 

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.